December 3rd, 2012
This week’s topics include the association between aldosterone-antagonist therapy and mortality and readmission among patients with HF and reduced EF, warfarin therapy after bioprosthetic AVR, and more.
May 7th, 2012
Roche announced today that it has ended development of dalcetrapib, its entry into the once-promising class of HDL-raising CETP inhibitors. A data and safety monitoring board recommended that the dal-OUTCOMES phase 3 trial be stopped due to a lack of clinically meaningful efficacy. The DSMB found no evidence of safety problems.